Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2019 11:41 ET | Source: Oryzon Genomics

ORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 2018

-$0.04/share for the 12 months ended December 31st MADRID, Spain and CAMBRIDGE, Mass., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public...
February 06, 2019 08:00 ET | Source: Oryzon Genomics

ORYZON Announces Publication of a relevant paper for the therapeutic development of Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC)

Complete and durable tumor regression occurred with Iadademstat–induced NOTCH activation in a chemoresistant PDX model Further supports LSD1 inhibitors as a possible new and targeted therapy for SCLC...
January 29, 2019 08:00 ET | Source: Oryzon Genomics

Oryzon to present at upcoming international conferences

21st Annual BIO CEO & Investor Conference 2019 in New York, USA12th Annual European Life Sciences CEO Forum in Zurich, Switzerland2019 BioCapital Europe in Amsterdam, The Netherlands31st Annual...
December 17, 2018 12:32 ET | Source: Oryzon Genomics

Oryzon to join the IBEX Small Cap Index

The inclusion will become effective on December 24th MADRID, Spain and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage...
November 02, 2018 08:00 ET | Source: Oryzon Genomics

ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2018

-$0.01/share for the 9 months ended September 30th MADRID, Spain and CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage...
October 17, 2018 08:00 ET | Source: Oryzon Genomics

ORYZON receives approval to start CLEPSIDRA: a Phase IIa clinical trial in Small Cell Lung Cancer with Iadademstat (ORY-1001)

The study will be done in SCLC patients in combination with Platinum-Etoposide chemotherapy MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code:...
October 09, 2018 08:00 ET | Source: Oryzon Genomics

Oryzon announces first patient enrolled in REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness

MADRID, Spain and CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), (“Oryzon”), a public clinical-stage biopharmaceutical company leveraging...
September 21, 2018 08:00 ET | Source: Oryzon Genomics

September 21st: World Alzheimer’s Day around the world

Working together to raise awareness and challenge the stigmaWith a concerted effort, science will prevail Oryzon has two ongoing clinical trials in AD with Vafidemstat MADRID, Spain and CAMBRIDGE,...
September 11, 2018 08:00 ET | Source: Oryzon Genomics

ORYZON receives approval to start ALICE: a Phase IIa clinical trial in AML with Iadademstat (ORY-1001)

The study will be done in elderly Acute Myeloid Leukemia (AML) patients not eligible for intensive chemotherapyIt is the first Phase II study of Iadademstat (ORY-1001) in combination therapy MADRID,...
September 07, 2018 08:40 ET | Source: Oryzon Genomics

Oryzon receives approval to begin REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness

The approval has been granted by the Spanish Medicines AgencyThe study will be done in patients with 3 psychiatric disorders and 2 neurodegenerative disordersThis is the first Phase IIa study with...